Scholar Rock (SRRK) Q1 2025 earnings summary

Executive summary

• Apitegromab achieved positive Phase 3 SAPPHIRE results in SMA, supporting FDA priority review (PDUFA date: September 22, 2025) and EMA validation, with U.S. commercial launch planned for Q3 2025 and European launch anticipated in 2026.

• Commercial readiness is progressing in the U.S. and Europe, with leadership expansion and fully staffed teams expected by mid-2025 to support global launch and growth.

• Pipeline expansion includes studies in other neuromuscular disorders (DMD, FSHD), cardiometabolic diseases, and obesity (EMBRAZE Phase 2 readout expected June 2025); IND for SRK-439 planned for Q3 2025.

• Management transition occurred in April 2025, with David Hallal appointed CEO and new executive team members.

Financial highlights

• Ended Q1 2025 with $364.4 million in cash, cash equivalents, and marketable securities, supporting commercial and R&D priorities.

• Net loss for Q1 2025 was $74.7 million ($0.67/share), up from $56.9 million ($0.59/share) in Q1 2024, driven by higher R&D and G&A expenses.

• Operating expenses rose to $77.1 million, with R&D at $48.7 million and G&A at $28.4 million.

• No revenue recorded for Q1 2025.

Outlook and guidance

• U.S. commercial launch of apitegromab expected in Q3 2025, pending FDA approval; European launch to begin in Germany in 2026.

• Phase 2 EMBRAZE topline data in obesity due June 2025; IND for SRK-439 expected Q3 2025; Phase 2 OPAL trial in infants/toddlers with SMA to initiate in Q3 2025.

• Cash runway projected to support operations and development through 2027, with additional capital needed for full development and commercialization.

• No formal revenue guidance provided, but optimism expressed due to newborn screening and concentrated centers of excellence in the U.S.